{'fraction_non_alphanumeric': 0.022556390977443608, 'fraction_numerical': 0.007518796992481203, 'mean_word_length': 5.833333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population

The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and liver fibrosis among middle‐aged and older people. Therefore, we aimed to determine the nationwide prevalence of and associated factors for MAFLD and fibrosis in adults aged 45–79 years from the United States.